Discovery of an LSD1 PROTAC degrader
10.1073/pnas.2425812122 · doi-reference
Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade
10.1016/j.cell.2016.11.022 · doi-reference
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities
10.1016/j.tips.2024.04.006 · doi-reference
Lactylation of LSD1 is an acquired epigenetic vulnerability of BRAFi/MEKi-resistant melanoma
10.1016/j.devcel.2025.02.016 · doi-reference
Lymph-node-derived stem-like but not tumor-tissue-resident CD8+ T cells fuel anticancer immunity
10.1038/s41590-025-02219-2 · doi-reference
Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1
10.1038/s41467-022-31998-7 · doi-reference
The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes
10.18632/aging.102887 · doi-reference
Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells
10.1016/j.celrep.2013.09.018 · doi-reference
Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses
10.1016/j.cell.2015.07.011 · doi-reference
TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors
10.1016/j.ccell.2025.09.011 · doi-reference
USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I
10.1172/jci193162 · doi-reference
E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC
10.1016/j.celrep.2023.113477 · doi-reference
Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies
10.3389/fimmu.2025.1664443 · doi-reference
JBI-802: the first orally available LSD1/HDAC6 dual inhibitor to enter clinical trials
10.1080/13543776.2025.2468792 · doi-reference
TNG260 is a small-molecule CoREST inhibitor that sensitizes STK11-mutant tumors to anti-PD-1 immunotherapy
10.1158/0008-5472.can-25-0998 · doi-reference
Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential
10.3389/fimmu.2023.1214675 · doi-reference
Landscape and treatment options of shapeshifting small cell lung cancer
10.3390/jcm13113120 · doi-reference
Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-cell killing
10.1158/1078-0432.ccr-22-1128 · doi-reference
Design, synthesis, and structure-activity relationship of TAK-418 and its derivatives as a novel series of LSD1 inhibitors with lowered risk of hematological side effects
10.1016/j.ejmech.2022.114522 · doi-reference
T-448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice
10.1038/s41386-018-0300-9 · doi-reference
A novel LSD1 inhibitor T-3775440 disrupts GFI1B-containing complex leading to transdifferentiation and impaired growth of AML cells
10.1158/1535-7163.mct-16-0471 · doi-reference
Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1
10.1016/j.molcel.2007.06.039 · doi-reference
